Quantcast

Molecular Breast Imaging Performs Better Than Ultrasound in Patients With Mammographic Abnormalities

December 1, 2008

CHICAGO, Dec. 1 /PRNewswire/ — For difficult to diagnose patients,
Breast-Specific Gamma Imaging (BSGI) is found to be a more useful adjunctive
imaging tool than ultrasound for patients who need additional imaging
following a questionable mammogram, this according to findings presented today
at the annual meeting of the Radiological Society of North America (RSNA).
BSGI is a molecular breast imaging technique that can see lesions independent
of tissue density and discover very early stage cancers.

“My colleagues and I found that in women who needed further examination
beyond mammography in the diagnosis of breast cancer, BSGI offered more
definitive answers than ultrasound,” said Dr. Jean Weigert, Director of
Women’s Imaging at Mandell and Blau M.D.’s PC, in New Britain, Conn.

Dr. Weigert conducted a study comparing BSGI to ultrasound in patients who
required additional imaging following a mammogram. As part of their diagnostic
evaluation, 70 patients had mammography, ultrasound, BSGI and biopsy. BSGI and
ultrasound had 96 percent and 58 percent sensitivity respectively and 55
percent and 43 percent specificity respectively. These results demonstrate
that BSGI may be more useful than ultrasound as an adjunctive imaging
technology to mammography.

BSGI for the study was conducted using a Dilon 6800 Gamma Camera, a
high-resolution, small field-of-view gamma camera, optimized to perform BSGI.
With BSGI, the patient receives a pharmaceutical tracing agent that is
absorbed by all the cells in the body. Due to their increased rate of
metabolic activity, cancerous cells in the breast absorb a greater amount of
the tracing agent than the normal surrounding tissue and generally appear as
“hot spots” on the BSGI image.

Dr. Weigert concluded that, “BSGI provided superior sensitivity and
comparable — if not better — specificity in this group of patients with
questionable mammograms requiring additional diagnostic imaging. BSGI may be a
more useful modality than ultrasound as an adjunct imaging technology to
mammography.”

About Dilon Technologies

Dilon Technologies Inc. is bringing innovative new medical imaging
products to market. Dilon’s cornerstone product, the Dilon 6800, is a
high-resolution, small field-of-view gamma camera, optimized to perform BSGI,
a molecular breast imaging procedure which images the metabolic activity of
breast lesions through radiotracer uptake. Many leading medical centers around
the country are now offering BSGI to their patients, including: Cornell
University
Medical Center, New York; George Washington University Medical
Center, Washington, D.C.; and The Rose, Houston.

For more information on Dilon Technologies please visit
http://www.dilon.com.

SOURCE Dilon Technologies Inc.


Source: newswire



comments powered by Disqus